Collecting Duct Carcinoma, from the CureRays guide library.

Collecting duct carcinoma is a rare, aggressive kidney cancer that begins deep in the kidney's drainage tubes and behaves more like an aggressive urinary-tract cancer, so it is treated mainly with chemotherapy alongside surgery rather than with the targeted pills used for common kidney cancers.

What it is.

Collecting duct carcinoma (also called Bellini duct carcinoma) is an uncommon and aggressive cancer that starts in the collecting ducts deep in the center of the kidney — the tubes that gather urine and funnel it toward the bladder. Although it grows in the kidney, its cells look and behave more like an aggressive cancer of the urinary tract lining (urothelial cancer), which is why it does not respond to the targeted and immune therapies that work for the common type of kidney cancer (clear cell). It tends to be found at a younger age than ordinary kidney cancer and is frequently advanced at diagnosis, often causing blood in the urine, flank pain, or weight loss. Because it spreads early and resists single treatments, care centers on platinum-based chemotherapy combined with surgery when possible, with radiation playing a supportive role.

How radiation treats it.

Radiation damages the DNA inside cancer cells so they can no longer grow and divide. In collecting duct carcinoma, chemotherapy and surgery do most of the work, but radiation is a valuable supportive tool: focused techniques such as SBRT can control an isolated area of spread, and targeted radiation can quickly relieve pain from a bone metastasis or stop bleeding, improving quality of life. Modern image guidance keeps the dose tightly on the target while sparing nearby organs. Radiation is painless, given over a short series of daily sessions, and leaves no radioactivity in the body.

The ways we can treat it.

Palliative external-beam radiation. Shaped radiation beams target painful or bleeding sites such as bone or lymph nodes to relieve symptoms quickly over a short course of treatments.

Stereotactic body radiation (SBRT). Delivers a few high, tightly focused doses to an isolated area of spread or a progressing spot, controlling it without an operation.

Conformal / image-guided (IGRT) photon radiation. Image-guided, intensity-modulated beams treat tumor in or near the kidney bed while sparing the bowel, spinal cord, and the remaining kidney.

Questions we hear often.

Is this the same as the common type of kidney cancer? No. Most kidney cancers are 'clear cell' renal cell carcinoma, which is treated with targeted pills and immunotherapy. Collecting duct carcinoma is rare and behaves like an aggressive urinary-tract cancer, so it is treated mainly with platinum-based chemotherapy and surgery instead.

Why is chemotherapy so central? Collecting duct carcinoma spreads early and is usually advanced when found, so a treatment that reaches the whole body is needed. Platinum-based chemotherapy is the most active option, with surgery used to remove the kidney when the disease is still removable.

What gives the best chance against such an aggressive cancer? Prompt care at a center experienced with rare kidney cancers, combining surgery when possible with platinum-based chemotherapy and radiation for symptom control. Because standard options are limited, clinical trials are an important and encouraged choice.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.